Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

The Clinical Significance of Chromosome 17 Abnormalities in Myelodysplastic Syndrome Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Blood (2017) 130 (Supplement 1): 1701.

https://doi.org/10.1182/blood.V130.Suppl_1.1701.1701

Published: 2017

Journal Articles

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study

Efstathios Kastritis, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, Maria Roussou, Evdoxia Hadjiharissi, Argyris Symeonidis, Panagiotis Repoussis, Evridiki Michalis, Sosana Delimpasi, Konstantinos Tsatalas, Panagiotis Tsirigotis, Amalia Vassou, Elina Vervessou, Eirini Katodritou, Dimitra Gika, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2015) 126 (11): 1392–1394.

https://doi.org/10.1182/blood-2015-05-647420

Published: 2015

Includes: Supplemental data

Journal Articles

Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study

Meletios A. Dimopoulos, MD, Maria Roussou, Efstathios Kastritis, Evdoxia Hadjiharissi, Marie-Christine Kyrtsonis, Argiris Symeonidis, MD, PhD, Panagiotis Repoussis, Eurydiki Michalis, Sosana Delimpasi, Konstantinos Tsatalas, Panagiotis Tsirigotis, Amalia Vassou, Elina Vervessou, Eirini Katodritou, Maria Gavriatopoulou, Dimitra Gika, Evangelos Terpos, Konstantinos Zervas

Blood (2012) 120 (21): 438.

https://doi.org/10.1182/blood.V120.21.438.438

Published: 2012

Journal Articles

No Significant Improvement In the Outcome of Patients with Waldenström's Macroglobulinemia Treated Over the Last 25 Years

Blood (2010) 116 (21): 3032.

https://doi.org/10.1182/blood.V116.21.3032.3032

Published: 2010

Journal Articles

The International Scoring System (ISS) for Multiple Myeloma Remains a Robust Prognostic Tool Independently of Patients' Renal Function

Blood (2010) 116 (21): 3036.

https://doi.org/10.1182/blood.V116.21.3036.3036

Published: 2010

Journal Articles

High Serum Levels of Angiogenic Cytokines in AL Amyloidosis Correlates with Disease Features.

Efstathios Kastritis, MD, Evangelos Terpos, MD, Mihail Mihail, MD, Konstantinos Anargyrou, MD, Sossana Delimpassi, MD, Marie Christine Kyrtsonis, MD, Evridiki Mihali, MD, Elina Vervessou, MD, Natalia Tzenou, MD, Panagiotis Repoussis, MD, Gerassimos Panagalis, MD, Meletios Athanasios Dimopoulos, MD

Blood (2007) 110 (11): 4781.

https://doi.org/10.1182/blood.V110.11.4781.4781

Published: 2007

Journal Articles

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Meletios A. Dimopoulos, MD, Athanasios Anagnostopoulos, M.D., Marie Christine Kyrtsonis, M.D., Constantinos Tsatalas, M.D., Garyfallia Kokkini, M.D., Panagiotis Repoussis, M.D., Athanasios Zomas, M.D., Argiris Symeonidis, M.D., Evridiki Michali, M.D., Nikolaos Anagnostopoulos, M.D., Evangelos Terpos, M.D., Theophanis Economopoulos, M.D., Gerasimos Pangalis, M.D.

Blood (2006) 108 (11): 128.

https://doi.org/10.1182/blood.V108.11.128.128

Published: 2006

Journal Articles

Macrofocal Multiple Myeloma in Young Patients: A Distinct Entity with Favorable Prognosis.

Meletios A. Dimopoulos, MD, Anastasia Pouli, MD, Athanasios Angnostopoulos, MD, Panagiotis Repoussis, MD, Argyris Symeonidis, MD, Souzana Delimbasi, MD, Fotis Tsolakis, MD, Constantinos Zervas, MD

Blood (2005) 106 (11): 3399.

https://doi.org/10.1182/blood.V106.11.3399.3399

Published: 2005

Journal Articles

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

Meletios A. Dimopoulos, MD, Panagiotis Repoussis, MD, Evangelos Terpos, MD, Maria Christina Kyrtsonis, MD, Athanasios Zomas, MD, Eirini Katodritou, MD, Souzana Delibasi, MD, Amalia Vassou, MD, Athanasios Anagnostopoulos, MD, Anastasia Pouli, MD, Konstantinos Zervas, MD, Dimitrios Margaritis, MD, Nikolaos Anagnostopoulos, MD, Alice G. Maniatis, MD

Blood (2004) 104 (11): 1482.

https://doi.org/10.1182/blood.V104.11.1482.1482

Published: 2004

Journal Articles

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Meletios A. Dimopoulos, MD, Maria Christina Kyrtsonis, MD, Constantinos Tsatalas, MD, Garyfallia Kokkini, MD, Panagiotis Repoussis, MD, Athanasios Zomas, MD, Argiris Symeonidis, MD, Evridiki Michali, MD, Athanasios Anagnostopoulos, MD, Nikolaos Anagnostopoulos, MD, Theophanis Economopoulos, MD, Gerasimos Pangalis, MD

Blood (2004) 104 (11): 752.

https://doi.org/10.1182/blood.V104.11.752.752

Published: 2004

Journal Articles

Symptomatic Multiple Myeloma in Young Adults ≤ 40 Years of Age.

Argiris Symeonidis, MD, Anastasia Pouli, MD, Panagiotis Repoussis, MD, Konstantinos Zervas, MD, Athanasios Anagnostopoulos, MD, Chrysanthi Mitsouli, MD, Dimitra Gika, Alice Maniatis, MD, Meletios Athanasios Dimopoulos, MD

Blood (2004) 104 (11): 4906.

https://doi.org/10.1182/blood.V104.11.4906.4906

Published: 2004

Journal Articles

Prognostic Factors and Outcome of Older Patients with Symptomatic Multiple Myeloma: A Study of the Greek Myeloma Study Group (GMSG).

Athanasios Anagnostopoulos, MD, Dimitra Gika, Argiris Symeonidis, MD, Konstantinos Zervas, MD, Anastasia Pouli, MD, Panagiotis Repoussis, MD, Vassiliki Grigoraki, MD, Nikolaos Anagnostopoulos, MD, Alice G. Maniatis, MD, Meletios Athanasios Dimopoulos, MD

Blood (2004) 104 (11): 4847.

https://doi.org/10.1182/blood.V104.11.4847.4847

Published: 2004

NARROW

The Clinical Significance of Chromosome 17 Abnormalities in Myelodysplastic Syndrome Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study

Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study

No Significant Improvement In the Outcome of Patients with Waldenström's Macroglobulinemia Treated Over the Last 25 Years

The International Scoring System (ISS) for Multiple Myeloma Remains a Robust Prognostic Tool Independently of Patients' Renal Function

High Serum Levels of Angiogenic Cytokines in AL Amyloidosis Correlates with Disease Features.

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Macrofocal Multiple Myeloma in Young Patients: A Distinct Entity with Favorable Prognosis.

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Symptomatic Multiple Myeloma in Young Adults ≤ 40 Years of Age.

Prognostic Factors and Outcome of Older Patients with Symptomatic Multiple Myeloma: A Study of the Greek Myeloma Study Group (GMSG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only